MedTrace Logo

PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

NCT06750432 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2025-12-24

No results posted yet for this study

Summary

This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.

Conditions

  • Alzheimer Disease, Early Onset

Interventions

DRUG

PMN310

A humanized immunoglobulin G1 (IgG1) monoclonal antibody

DRUG

Placebo

0.9% NaCl 100 mL

Sponsors & Collaborators

  • ProMis Neurosciences, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-13
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06750432 on ClinicalTrials.gov